KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Retained Earnings (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Retained Earnings for 11 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 100.35% to $4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Dec 2025, up 100.35% year-over-year, with the annual reading at $4.8 million for FY2025, 100.35% up from the prior year.
  • Retained Earnings hit $4.8 million in Q4 2025 for CRISPR Therapeutics AG, down from $5.0 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $72.5 million in Q2 2021 to a low of -$1.7 billion in Q2 2025.
  • Historically, Retained Earnings has averaged -$462.7 million across 5 years, with a median of -$38.5 million in 2021.
  • Biggest YoY gain for Retained Earnings was 119.38% in 2021; the steepest drop was 3815116.67% in 2021.
  • Year by year, Retained Earnings stood at -$195.9 million in 2021, then crashed by 331.87% to -$846.1 million in 2022, then surged by 100.23% to $1.9 million in 2023, then plummeted by 71503.66% to -$1.4 billion in 2024, then surged by 100.35% to $4.8 million in 2025.
  • Business Quant data shows Retained Earnings for CRSP at $4.8 million in Q4 2025, $5.0 million in Q3 2025, and -$1.7 billion in Q2 2025.